<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26784">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01967615</url>
  </required_header>
  <id_info>
    <org_study_id>P2BiTO13</org_study_id>
    <secondary_id>2013-100813</secondary_id>
    <nct_id>NCT01967615</nct_id>
  </id_info>
  <brief_title>P2Y12 Inhibitor Utilization in Bifurcation and Chronic Total Occlusion PCI With Multiple DES (P2BiTO) Registry</brief_title>
  <acronym>P2BiTO</acronym>
  <official_title>P2Y12 Inhibitor Utilization in Bifurcation and Chronic Total Occlusion Percutaneous Coronary Intervention With Multiple Drug-eluting Stent (P2BiTO) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prasugrel and ticagrelor were both associated with a significant reduction in the risk of
      MACE in patients undergoing PCI for an ACS, mostly through a reduced stent thrombosis. The
      1-year relative risk reduction (RRR) of definite of probable stent thrombosis in patients
      receiving a DES were fairly different in TRITON-TIMI 38 and PLATO trials. The incidence of
      DES thrombosis is largely variable according to different lesion settings. We aim to verify
      the translation of the postulated different reduction in thrombosis rate among various P2Y12
      inhibitors (clopidogrel, prasugrel and ticagrelor) in a high-risk setting such as the
      presence of ≥2 overlapping DES in CTO and bifurcation lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients aged 18-80 undergoing PCI of a CTO or bifurcating lesion with ≥2 overlapping
      DES at participating centers and discharged with either prasugrel or ticagrelor will be
      deemed eligible to enter the registry.

      In-hospital outcomes will be recorded; all patients discharged alive will be followed up
      with a 30-day and 6-month telephone interview and a 1-year visit.

      The primary end-point will be the occurrence of a cluster of major adverse cardiovascular
      events at 1 year:

        1. Death from any cause.

        2. Myocardial infarction, defined as an elevation of the creatine kinase MB fraction or
           cardiac troponins by a factor of 3 or more, or the development of new Q waves in 2 or
           more contiguous leads at surface ECG7. Levels of total creatine kinase and the creatine
           kinase MB fraction will be measured in all patients between 12 and 24 hours after PCI.

        3. Stent thrombosis, defined as definite, probable or possible3 following the Academic
           Research Consortium.

      Assuming a 1-year rate of death, myocardial infarction and stent thrombosis of 12% among
      patients with &quot;overlapping DES&quot; taking ticagrelor, an overall sample size of 578 patients in
      each group would allow to detect a reduction of 40% in the occurrence of the combined
      primary end-point among prasugrel as compared to ticagrelor patients. By estimating a 5%
      drop-off rate during the 1-year follow-up, 603 patients will have to be enrolled in each arm
      and therefore a total of 1810 patients will be screened in the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Death, Myocardial infarction, Stent Thrombosis</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Death from any cause.
Myocardial infarction, defined as an elevation of the creatine kinase MB fraction or cardiac troponins by a factor of 3 or more, or the development of new Q waves in 2 or more contiguous leads at surface ECG7. Levels of total creatine kinase and the creatine kinase MB fraction will be measured in all patients between 12 and 24 hours after PCI.
Stent thrombosis, defined as definite, probable or possible3 following the Academic Research Consortium</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients aged 18-80 undergoing PCI of a CTO or bifurcating lesion with ≥2 overlapping
        DES at participating centers and discharged with either prasugrel or ticagrelor will be
        deemed eligible to enter the registry
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-80 years old

          -  PCI of a CTO or bifurcating lesion with ≥2 overlapping DES

          -  Therapy with either prasugrel or ticagrelor

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Zimarino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G. d'Annunzio University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raffaele De Caterina, MD/PhD</last_name>
    <phone>+39 0871 41512</phone>
    <email>rdecater@unich.it</email>
  </overall_contact>
  <reference>
    <citation>Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.</citation>
    <PMID>17982182</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283-93. doi: 10.1016/S0140-6736(09)62191-7. Epub 2010 Jan 13.</citation>
    <PMID>20079528</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK; PLATO Study Group. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 3;128(10):1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589. Epub 2013 Jul 30.</citation>
    <PMID>23900047</PMID>
  </reference>
  <reference>
    <citation>Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G, Dovellini EV, Antoniucci D. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. J Am Coll Cardiol. 2013 Feb 5;61(5):545-50. doi: 10.1016/j.jacc.2012.10.036. Epub 2012 Dec 26.</citation>
    <PMID>23273395</PMID>
  </reference>
  <reference>
    <citation>Zimarino M, Corazzini A, Ricci F, Di Nicola M, De Caterina R. Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. JACC Cardiovasc Interv. 2013 Jul;6(7):687-95. doi: 10.1016/j.jcin.2013.03.012. Epub 2013 Jun 14.</citation>
    <PMID>23769650</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24.</citation>
    <PMID>22922414</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>Raffaele De Caterina</investigator_full_name>
    <investigator_title>MD/PhD</investigator_title>
  </responsible_party>
  <keyword>PCI,</keyword>
  <keyword>CTO,</keyword>
  <keyword>bifurcation,</keyword>
  <keyword>clopidogrel,</keyword>
  <keyword>prasugrel,</keyword>
  <keyword>ticagrelor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
